Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP262 in chronic spontaneous urticaria
NCT06077773Phase 2Terminated
- Sponsor
- Escient Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of EP262 in chronic spontaneous urticaria (CSU), sponsored by Escient Pharmaceuticals. Started Sep 2023; status: terminated.
02
Drugs
EP262
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06077773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06077773.